Cancers of the brain and
nervous system affect nearly 24,000 people annually, suggests the National Cancer Institute. In 2013, there were
an estimated 152,751 people living with brain and other nervous system
cancer in the United States. The overall five-year survival rate is 33.8%.
Knowing the probable survival status of an individual patient may help physicians choose the best treatment.
‘The new biomarker for glioma can help doctors determine how aggressive a cancer is and could eventually help determine the best course of treatment.’
Researchers at UT Southwestern Medical Center have found a new
biomarker for glioma, a common type of brain cancer, that can help
doctors determine how aggressive a cancer is and that could eventually
help determine the best course of treatment.
Researchers from the Harold C. Simmons Comprehensive Cancer Center found that high expression of a gene called SHOX2
predicted poor survival in intermediate grade gliomas.
"As an independent biomarker, SHOX2
expression is as potent as the currently best and widely used marker known as IDH mutations," said Dr. Adi Gazdar, Professor of Pathology in the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology and a member of the Simmons Cancer Center.
In combination with IDH mutations or several other biomarkers, SHOX2
expression helped to identify subgroups of patients with a good
prognosis even though other biomarkers had predicted a bad prognosis.
"Our findings are based on analysis of previously published studies.
They will have to be confirmed in prospective studies, and their
clinical contribution and method of use remain to be determined," said
Dr. Gazdar, who holds the W. Ray Wallace Distinguished Chair in
Molecular Oncology Research.
The findings are published in EBiomedicine